TD-0212 TFA |
Catalog No.GC38856 |
TD-0212 TFA es un antagonista del receptor (AT1) de angiotensina II tipo 1 de farmacologÍa dual activo por vÍa oral y un inhibidor de la neprilisina (NEP), con un pKi de 8,9 para AT1 y un pIC50 de 9,2 para NEP.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1073549-11-7
Sample solution is provided at 25 µL, 10mM.
TD-0212 TFA is an orally active dual pharmacology angiotensin II type 1 receptor (AT1) antagonist and neprilysin (NEP) inhibitor, with a pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP[1].
TD-0212 provides the enhanced activity of dual AT1/NEP inhibition with a potentially lower risk of angioedema relative to dual ACE/NEP inhibition[1].
TD-0212 produces blood pressure reductions similar to omapatrilat and combinations of AT1 receptor antagonists and NEP inhibitors in models of renin-dependent and -independent hypertension[1].
[1]. McKinnell RM, et al. Discovery of TD-0212, an Orally Active Dual Pharmacology AT1 Antagonist and Neprilysin Inhibitor (ARNI). ACS Med Chem Lett. 2018 Dec 3;10(1):86-91.
Average Rating: 5
(Based on Reviews and 3 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *